Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief Medical Officer | January 09, 2020 | January 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protara Therapeutics, Inc.
Report date January 09, 2020 · Filed January 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,500 |
Reported balance
After 2020-01-10 transaction · row 1
1 source rowRow 1 · 2020-01-10 · Grant · Acquired 45,500 · Balance 45,500 F1: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18 · Expires 2029-04-28 | Direct | 38,151 |
Reported balance
After 2020-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-09 · Grant · Acquired 38,151 · Balance 38,151 F2: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4: Received in the Merger in exchange for an employee stock option to acquire 200,000 shares of ArTara Sub common stock for $1.75 per share. F3: 1/48th of the shares subject to the option shall vest monthly following February 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020.
F2: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.
F3: 1/48th of the shares subject to the option shall vest monthly following February 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer.
F4: Received in the Merger in exchange for an employee stock option to acquire 200,000 shares of ArTara Sub common stock for $1.75 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2020 Filed Jan 14, 2020 00:09 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 45,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003231 · doc4.xml · nonDerivative · entry 1 Casoy Julio · CIK 0001799076 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 25% of the shares vest on each one-year anniversary of January 10, 2020. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:09 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 38,151 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003231 · doc4.xml · derivative · entry 2 Casoy Julio · CIK 0001799076 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,151 Underlying: Common Stock · 38,151 shares Expires 2029-04-28 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4 · price: Received in the Merger in exchange for an employee stock option to acquire 200,000 shares of ArTara Sub common stock for $1.75 per share. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following February 1, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.